Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05039970
Other study ID # 00055024
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2021
Est. completion date October 31, 2022

Study information

Verified date October 2022
Source BioCentric, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall prevalence of type 2 diabetes in the United States (US) is estimated at more than 30 million people, with an estimated 88 million more adults meeting the criteria for having prediabetes and being at risk for progressing to type 2 diabetes. The significant burden of diabetes, as well as the high individual and societal cost it bears, renders this disease among the highest public health priorities for the health authorities and policy makers. In response to the rising diabetes prevalence, the US Centers for Disease Control and Prevention (CDC) established the National Diabetes Prevention Program (National DPP) in 2010 as a framework for diabetes prevention by providing evidence-based, affordable, and high-quality lifestyle change programs (LCPs). The National DPP LCP is a yearlong education-based curriculum focused on achieving modest weight loss (5% to 7%) and increasing participants' physical activity to reduce the risk of progressing to type 2 diabetes. To ensure high-quality programs and meaningful impact on participants, the CDC sets standards for organizations that wish to offer an LCP through the Diabetes Prevention Recognition Program (DPRP). The DPRP plays a critical role in ensuring that organizations can effectively deliver the evidence-based lifestyle change program with quality and fidelity. To achieve recognition status, organizations must periodically provide evidence that they are following a CDC-approved curriculum and achieving meaningful results on session attendance, body weight change, and physical activity minutes. A recent analysis of National DPP data has shown that the attrition rates in this program are substantial and that they differ by age and race. Moreover, the attrition rates were inversely associated with the program success, as reflected by the LCP outcomes, and, specifically, participants' weight and level of physical activity. In view of these findings, the CDC is undertaking an effort to increase participant retention in the National DPP. The proposed study will evaluate the pilot use of a free-of-charge mobile device-based serious health game (WellQuest™) within the frame of the National DPP LCP. WellQuest™ was designed with the goals to improve participant engagement and retention in the LCP, to encourage adoption and maintenance of healthy lifestyle habits among LCP participants, and to reinforce knowledge of the LCP curriculum.


Recruitment information / eligibility

Status Completed
Enrollment 550
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Enrollment in a qualifying National DPP program - Body mass index (BMI) =25 kg/m2 for non-Asians and =23 kg/m2 for Asians. - Have prediabetes identified by either a blood test or a self-reported risk test or have a history of gestational diabetes mellitus (GDM). Exclusion Criteria: - Participants cannot have a previous diagnosis of type 1 or type 2 diabetes, prior to enrollment in a National DPP.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
WellQuest™
WellQuest™ is a mobile device-based serious health game.

Locations

Country Name City State
United States BioCentric, Inc. Collingswood New Jersey

Sponsors (2)

Lead Sponsor Collaborator
BioCentric, Inc. Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Completeness of health data collected by the game Proportion of participants reporting health data via game 6 Months
Other Comparability of health data collected by the game and data reported by the organization Percentage of health data reported in game versus the cohort data reported to CDC 6 Months
Other Body weight (and/or body mass index [BMI]) change over time Change in body weight measured in pounds over study duration 6 Months
Other Correlation between any weight loss (and/or BMI decrease) and game use Change in body weight measured in pounds in proportion to game use measured in minutes 6 Months
Other Correlation of >5% weight loss and game use Game use measured in minutes among those who achieved >5% weight loss 6 Months
Other Correlation of increased physical activity and game use Change in physical activity measured in minutes in proportion to game use measured in minutes 6 Months
Other Correlation between retention in National DPP 6 months after enrollment and the amount of time spent playing the serious health game during the first month after enrollment Number of sessions in proportion to duration of game play during the first month (measured in minutes) 6 Months
Other Number of sessions attended in the experimental cohort among those who downloaded the game and those who did not download the game Number of sessions attended as reported by the CDC among those who did and did not download the game as measured by number of downloads 6 Months
Other Fitness tracker integration with the game. Proportion of game players who link fitness tracker to the game as measured by in-game analytics 6 Months
Primary Number of Sessions Attended The primary outcome of this study is the number of sessions attended during the first 6 months following enrollment in a National DPP. 6 Months
Secondary Retention in National DPP 4 months and 6 months after enrollment. This outcome would be retention reported in number of sessions at 4 months and 6 months after enrollment. 6 Months
Secondary Game downloads among participants randomized to the experimental arm Proportion of participants who download the game 6 Months
Secondary Daily time spent playing the serious health game in participants who downloaded the game. Amount of time in minutes spent by participants playing the game Six Months
Secondary Participants' game rating/Net Promoter Score or questionnaire. Likert scale rating of participants' satisfaction questionnaire (willingness to recommend to others) Six Months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT03462420 - Physiotherapy Program for Managing Adhesive Capsulitis in Patients With Diabetes N/A